City Therapeutics (NASDAQ:CTY) Stock Rated “Early-Stage Biotech” in New Coverage at The Goldman Sachs Group

Posted by Tammy Falkenburg on Nov 10th, 2026

Investment analysts at The Goldman Sachs Group began coverage on shares of City Therapeutics (NASDAQ:CTY – Get Free Report) in a research note issued on Tuesday, Benzinga reports. The brokerage set an “early-stage biotech” rating on the stock.

A number of other equities analysts have also commented on CTY. Jefferies Financial Group began coverage on shares of City Therapeutics in a research report on Tuesday. They set a “buy” rating and a $32.00 target price on the stock. Wall Street Zen upgraded City Therapeutics to a “hold” rating in a report on Saturday, October 24th. Finally, Oppenheimer started coverage on City Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $46.00 price objective on the stock. Three analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $37.33.

Check Out Our Latest Stock Report on CTY

City Therapeutics Price Performance

Shares of CTY opened at $18.67 on Tuesday. City Therapeutics has a 1-year low of $15.81 and a 1-year high of $23.88.

Insider Transactions at City Therapeutics

In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc bought 170,000 shares of the business’s stock in a transaction on Monday, October 19th. The shares were acquired at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the transaction, the insider owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert Nelsen purchased 170,000 shares of City Therapeutics stock in a transaction dated Monday, October 19th. The stock was acquired at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.